Show simple item record

dc.contributor.authorPritchard-Jones, K
dc.contributor.authorMoroz, V
dc.contributor.authorVujanic, G
dc.contributor.authorPowis, M
dc.contributor.authorWalker, J
dc.contributor.authorMessahel, B
dc.contributor.authorHobson, R
dc.contributor.authorLevitt, G
dc.contributor.authorKelsey, A
dc.contributor.authorMitchell, C
dc.contributor.authorCCLG, CSCLG
dc.contributor.authorGrp, RT
dc.date.accessioned2018-08-08T08:51:19Z
dc.date.issued2012-09
dc.identifier9
dc.identifier.citationANNALS OF ONCOLOGY, 2012, 23 pp. 2457 - 2463
dc.identifier.issn0923-7534
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2291
dc.identifier.doi10.1093/annonc/mds025
dc.description.abstractThe randomised findings of the UKW3 trial were that preoperative chemotherapy was associated with a more advantageous stage distribution and reduction in therapy burden versus immediate nephrectomy without compromising outcome in localised Wilms’ tumour (WT). We analysed outcome in all WT registered in UKW3. Seven hundred and eighteen WT cases (7% anaplastic) were registered in UKW3. We assigned a treatment stage and conducted survival analysis. Five-year event-free survival (EFS) and overall survival (OS) were 77.2% [95% confidence interval (CI) 73.9-80.2] and 87.5% (95% CI 84.8-89.7) after median follow-up of 9.5 years and 10.0 years, respectively. Five-year OS in localised non-anaplastic cases was 92.9% (95% CI 90.2-94.9). Anaplasia was associated with adverse outcome compared with non-anaplastic cases: 5-year EFS of 42.0% (95% CI 28.3-55.1) versus 79.8% (95% CI 76.5-82.7) and 5-year OS of 60% (95% CI 45.1-72.0) versus 89.6% (95% CI 87.0-91.7), respectively. Outcomes were similar for non-anaplastic stage I or II but significantly poorer in stage III cases than stage I. Five-year OS after relapse was 54.1% (95% CI 44.5-62.8). Forty-seven percent of non-anaplastic WT received anthracycline; 27% were treated with radiotherapy first line. These outcomes provide a baseline for future comparisons of WT treatment approach, burden and patient outcome.
dc.format.extent2457 - 2463
dc.languageeng
dc.language.isoeng
dc.publisherOXFORD UNIV PRESS
dc.titleTreatment and outcome of Wilms’ tumour patients: an analysis of all cases registered in the UKW3 trial
dc.typeJournal Article
rioxxterms.versionofrecord10.1093/annonc/mds025
rioxxterms.licenseref.startdate2012-09
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfANNALS OF ONCOLOGY
pubs.notesaffiliation: Pritchard-Jones, K (Reprint Author), UCL, Inst Child Hlth, Mol Haematol & Canc Biol Unit, 30 Guilford St, London WC1N 1EH, England. Pritchard-Jones, K., UCL, Inst Child Hlth, Mol Haematol & Canc Biol Unit, London WC1N 1EH, England. Moroz, V., Univ Birmingham, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England. Vujanic, G., Cardiff Univ, Sch Med, Dept Pathol, Cardiff, S Glam, Wales. Powis, M., Leeds Teaching Hosp NHS Trust, Dept Paediat Surg, Leeds, W Yorkshire, England. Walker, J., Royal Hallamshire Hosp, Dept Paediat Surg, Sheffield S10 2JF, S Yorkshire, England. Messahel, B., Inst Canc Res, Sect Paediat Oncol, Sutton, Surrey, England. Hobson, R., Univ Leicester, Dept Hlth Sci, Leicester, Leics, England. Levitt, G., Great Ormond St Hosp Sick Children, Dept Haematol & Oncol, London WC1N 3JH, England. Kelsey, A., Royal Manchester Childrens Hosp, Dept Pathol, Manchester M27 1HA, Lancs, England. Mitchell, C., Oxford Radcliffe Hosp NHS Trust, Dept Paediat Oncol, Oxford, England. keywords: survival; treatment evaluation; Wilms’ tumour keywords-plus: CANCER-STUDY-GROUP; MANAGEMENT; SURVIVAL; CHILDREN research-areas: Oncology web-of-science-categories: Oncology author-email: [email protected] researcherid-numbers: Pritchard-Jones, Kathy/F-4286-2014 orcid-numbers: Pritchard-Jones, Kathy/0000-0002-2384-9475 funding-acknowledgement: CCLG; UK Children’s Cancer and Leukaemia Group funding-text: The authors thank all clinicians caring for children at participating hospitals in the UKW3 trial and the staff at the Children’s Cancer and Leukaemia Group (CCLG) data centre. The authors wish to acknowledge the contribution of Rosemary Shannon (Department of Paediatric Haematology/Oncology, Leicester Royal Infirmary, UK) and Peter Gornall (Department of Surgery, Birmingham Children’s Hospital, UK) to the UKW3 study. The authors thank Dr Aidan McManus for writing and editorial assistance during manuscript preparation, funded by CCLG charitable donations.; This analysis was supported by the UK Children’s Cancer and Leukaemia Group. number-of-cited-references: 17 times-cited: 33 usage-count-last-180-days: 0 usage-count-since-2013: 3 journal-iso: Ann. Oncol. doc-delivery-number: 995NU unique-id: ISI:000308017000037 oa: gold_or_bronze da: 2018-08-08
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.volume23
pubs.embargo.termsNot known
dc.contributor.icrauthorMessahel, Ben


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record